Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
May 2, 2019 Off

bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress

By BusinessWire

– Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years…

May 2, 2019 Off

bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress

By BusinessWire

– Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years…

May 2, 2019 Off

Gilead Sciences Announces First Quarter 2019 Financial Results

By BusinessWire

– Product Sales of $5.2 billion –– Diluted EPS of $1.54 per share –– Non-GAAP Diluted EPS of $1.76 per…

May 2, 2019 Off

Ligand Reports First Quarter 2019 Financial Results

By BusinessWire

Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results…

May 2, 2019 Off

Ligand Reports First Quarter 2019 Financial Results

By BusinessWire

Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results…

May 2, 2019 Off

Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

By BusinessWire

IRVINE, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24NVUS&src=ctag" target="_blank"gt;$NVUSlt;/agt;–Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with…

May 2, 2019 Off

Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

By BusinessWire

IRVINE, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24NVUS&src=ctag" target="_blank"gt;$NVUSlt;/agt;–Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with…

Teva posts $4.3 billion revenue in first quarter 2019
May 2, 2019 Off

Teva posts $4.3 billion revenue in first quarter 2019

By BusinessWire

Revenues of $4.3 billion GAAP diluted loss per share of $0.10 Non-GAAP diluted EPS of $0.60 Free cash flow of…

Celgene and bluebird bio happy with expansion and persistence ofthe CAR T-cells seen in Phase 1 Study
May 2, 2019 Off

Celgene and bluebird bio happy with expansion and persistence ofthe CAR T-cells seen in Phase 1 Study

By BusinessWire

Cellgene and bluebird bio are are encouraged by the expansion and persistence ofthe CAR T-cells, as well as the deep and durable responses with amanageable safety profile we’ve seen for bb2121 to date

May 2, 2019 Off

Arrhythmias Pipeline Review, H1 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Arrhythmias – Pipeline Review, H1 2019” report has been added to ResearchAndMarkets.com’s offering. This latest pipeline guide Arrhythmias…

Posts pagination

Previous 1 … 3,229 3,230 3,231 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine